Compare prices and buy FOXO4-DRI from 14 research peptide vendors - also called suppliers or sources. Updated daily.
A 46-residue synthetic senolytic peptide (CAS 2460055-10-9, C228H388N86O64) that copies residues 96 to 124 of human FOXO4 in reversed order and in D-amino-acid form, apart from its achiral glycines, fused to a reversed HIV-TAT segment that carries it into cells. In its developers' cell studies it outcompeted FOXO4 for binding to p53, excluded active p53 from the nucleus and triggered caspase-dependent apoptosis in senescent human fibroblasts. Preclinical, studied only in cells and animals, with no registered or published human study.
For research purposes only. Not medical advice.
FOXO4-DRI is a synthetic research peptide sold as a senolytic, a compound intended to kill senescent cells. Senescent cells stop dividing after damage and secrete inflammatory factors, and clearing them is the idea the compound was built to test. Product copy around it reaches past that, into reversing aging. What exists is cell-culture and mouse work from 2017 onward, and no study of it in people has been registered or published.
The molecule has 46 residues (CAS 2460055-10-9, C228H388N86O64). Twenty-nine of them copy positions 96 to 124 of human FOXO4, a forkhead transcription factor, in reversed order and in D-amino-acid form, which is what D-retro-inverso describes. The other 17 are a reversed HIV-TAT segment that carries the peptide into cells. Glycine is achiral, so the four glycines are neither D nor L and the common claim that every residue is a D-amino acid is loose.
The compound comes from Peter de Keizer's laboratory, then at Erasmus University Medical Center in Rotterdam, and was described by Baar and colleagues in Cell in 2017. That paper reported FOXO4 holding p53 in the nucleus of senescent cells and keeping them alive, and the peptide was designed to break that interaction.
NMR titrations in the paper show the peptide outcompeting FOXO4 for binding to p53, the opposite direction from the way product copy usually states it. In senescent human IMR90 fibroblasts it excluded active p53 from the nucleus and activated caspase-3/7, reducing viability 11.73-fold more in senescent cells than in proliferating controls. The same sequence in ordinary L-form did nothing, and neither did a D-retro-inverso peptide built from a different forkhead protein, so the reversed all-D architecture carries the activity.
A 2025 structural study in Nature Communications found the peptide binding the disordered transactivation domain of p53 as a transient complex, with its cationic carrier segment also contributing, and found that phosphorylation of p53 raises the affinity.
Baar and colleagues used three mouse models, and every endpoint was a tissue, blood or behavior measure.
That paper measured no survival or lifespan endpoint in any model, and in the naturally aged cohort running-wheel variation was too wide to analyze. The widely repeated claim that it extended median lifespan by 24.8 percent appears in no part of it, and no indexed study reports such a figure for this peptide.
Other groups have since reported their own models: senescent Leydig cells and testosterone output in aged mice (Aging, 2020), sperm measures in aged mice (Experimental Gerontology, 2024), expanded human chondrocytes, where it lowered senescence markers without improving cartilage-forming capacity (Frontiers in Bioengineering and Biotechnology, 2021), keloid fibroblasts and organ cultures (Communications Biology, 2025), aortic endothelium in aged and progeroid mice (Frontiers in Bioengineering and Biotechnology, 2025), and bleomycin-induced lung fibrosis (Journal of Cellular and Molecular Medicine, 2022). All of it is cell-culture or animal research.
Cleara Biotech, the Utrecht company founded on this discovery with de Keizer as founder and chief scientific officer, is not advancing FOXO4-DRI itself. Its August 31, 2026 release describes two optimized all-D peptides of its own, CL04177 and CL04183, directed at cancers with impaired p53 signaling, with CL04183 ready for a first-in-human filing and a trial planned for 2027.
As of October 20, 2026 FOXO4-DRI appears in none of the following: Drugs@FDA, either table of FDA's Category 2 bulk drug substances page (current as of April 22, 2026), the Section 503A nomination categories (updated May 14, 2026) or the Section 503B categories (updated March 21, 2025), the substances FDA named for its October 2024 and July 2026 Pharmacy Compounding Advisory Committee meetings, FDA's substance registry GSRS, ClinicalTrials.gov, or FDA's warning-letter database.
No published study reports that. The 2017 paper in Cell that introduced the peptide measured no survival or lifespan endpoint in any of its three mouse models. In naturally aged mice it reported a drop in a p16 senescence reporter and improvements in fur density, responsiveness to gentle stimuli, plasma urea and plasma creatinine, and in fast-aging mice it also reported running-wheel activity. The figure of 24.8 percent for median lifespan, repeated widely in product and secondary copy, appears nowhere in that paper, and a search of PubMed and Europe PMC on October 20, 2026 found no indexed study reporting it for this peptide.
No. ClinicalTrials.gov lists no registered study of it as of October 20, 2026, and PubMed returns no clinical record. The company founded on the discovery, Cleara Biotech of Utrecht, is advancing two optimized peptides of its own, CL04177 and CL04183, directed at cancers with impaired p53 signaling. Its release of August 31, 2026 says CL04183 is ready for a first-in-human regulatory filing with a trial planned for 2027. That program is a different molecule from the FOXO4-DRI research vendors sell.
The peptide reproduces residues 96 to 124 of human FOXO4 with the residue order reversed and the amino acids in their D form, an approach meant to present a similar side-chain arrangement while resisting the enzymes that cut natural peptides. A reversed HIV-TAT segment of 17 residues is attached to carry it into cells, giving 46 residues in total, the formula C228H388N86O64 and an average mass near 5358. Glycine is achiral, so the four glycines are neither D nor L. In the 2017 paper the ordinary L-form of the same sequence had no effect on senescent cells.
In the 2017 paper, using human IMR90 fibroblasts made senescent by irradiation, the peptide reduced viability 11.73-fold more in senescent cells than in proliferating controls, and it activated caspase-3/7 only in the senescent ones. Knocking down p53 or adding a pan-caspase inhibitor blunted the effect, which is the evidence behind the stated mechanism. Selectivity in a cell line is not selectivity in a body, and the published record for this peptide stops at cells and animals.
No. As of October 20, 2026 it holds no FDA approval and appears in no Drugs@FDA application. It is absent from both tables of FDA's Category 2 bulk drug substances page, from the Section 503A nomination categories updated May 14, 2026 and the Section 503B categories updated March 21, 2025, and from the substance lists FDA published for its October 2024 and July 2026 Pharmacy Compounding Advisory Committee meetings. FDA's substance registry holds no record of it and no warning letter names it. None of those absences is a safety finding in either direction.
FOXO4-DRI is sold by 14 research peptide vendors indexed on PeptideScouter, with 20 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
12 of the 14 indexed vendors currently have FOXO4-DRI in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Iron Protocol currently lists FOXO4-DRI at $7.98/mg, the lowest listed price across 14 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $5.64/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 14 vendors listing FOXO4-DRI publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $6.26/mg listed to $5.64/mg at Alpha Peptides. Each vendor's code is shown beside its price in the table above.
FOXO4-DRI ranges from $6.26/mg to $21.60/mg across 20 listings from 14 research peptide vendors, normalized to USD per milligram and refreshed daily.
14 research peptide vendors currently list FOXO4-DRI on PeptideScouter, with 12 in stock right now. We track 20 listings across size and kit variants.
FOXO4-DRI's CAS Registry Number is 2460055-10-9. It is also sold as FOXO4-DRI, FOX04-DRI.
